|
Table 1. In Vitro Susceptibilities of Elizabethkingia and Chryseobacterium Species a |
|
|||||||
|
Antibiotic |
n |
Range |
MIC50 |
MIC90 |
Breakpoint b |
% Susceptible |
Reference |
|
|
Minocycline |
58 |
<0.25-4 |
1 |
2 |
<4 |
100 |
(47) c |
|
|
Levofloxacin |
58 |
<0.5-8 |
1 |
2 |
<2 |
98 |
(47) |
|
|
Gentamicin |
19 |
4->64 |
>64 |
>64 |
<4 |
|
(66)d |
|
|
Gentamicin |
28 |
32->128 |
64 |
>128 |
<4 |
0 |
(1) e |
|
|
Cefazolin |
28 |
128->128 |
128 |
>128 |
<8 |
0 |
(1) |
|
|
Cefepime |
58 |
<1->64 |
64 |
>64 |
<4 |
10 |
(47) |
|
|
Cefotaxime |
19 |
4->64 |
64 |
>64 |
<8 |
|
(66) |
|
|
Cefoxitin |
28 |
4-64 |
8 |
16 |
<8 |
|
(1) |
|
|
Ceftazidime |
19 |
1->64 |
>64 |
>64 |
<8 |
|
(66) |
|
|
Cephalothin |
28 |
128->128 |
>128 |
>128 |
<8 |
0 |
(1) |
|
|
Aztreonam |
19 |
>64 |
>64 |
>64 |
<8 |
|
(66) |
|
|
Imipenem |
19 |
2->16 |
>16 |
>16 |
<4 |
|
(66) |
|
|
Imipenem |
58 |
2->16 |
>16 |
>16 |
<4 |
17 |
(47) |
|
|
Meropenem |
19 |
2->16 |
16 |
>16 |
|
|
(66) |
|
|
Meropenem |
58 |
2->16 |
>16 |
>16 |
<4 |
7 |
(47) |
|
|
Tetracycline |
28 |
16-64 |
32 |
64 |
<4 |
0 |
(1) |
|
|
Ampicillin |
28 |
64->128 |
>128 |
>128 |
|
|
(1) |
|
|
Ampicillin |
18 |
1->128 |
>128 |
>128 |
|
|
(52) |
|
|
Amoxicillin-clavulinic acid |
18 |
1-32 |
>32 |
>32 |
|
|
(52) |
|
|
Piperacillin |
19 |
<2-256 |
64 |
128 |
<16 |
|
(66) |
|
|
Piperacillin-tazobactam |
58 |
<2->128 |
64 |
>128 |
<16/4 |
29 |
(47) |
|
|
Ticarcillin |
19 |
32->256 |
256 |
>256 |
<16 |
|
(66) |
|
|
Ticarcillin-clavulinic acid |
19 |
8->256 |
128 |
>256 |
<16/2 |
|
(66) |
|
|
Ticarcillin-clavulinic acid |
58 |
16->128 |
>128 |
>128 |
<16/2 |
2 |
(47) |
|
|
Cefclidin |
22 |
0.78->100 |
50 |
>100 |
|
|
(127) |
|
|
Ciprofloxacin |
19 |
0.25->8 |
1 |
4 |
<1 |
|
(66) |
|
|
Ciprofloxacin |
58 |
0.5-16 |
2 |
8 |
<1 |
48 |
(47) |
|
|
Clinafloxacin |
58 |
<0.12-2 |
0.25 |
1 |
|
|
(47) |
|
|
Rifampicin |
28 |
0.25-2 |
1 |
2 |
<1 |
|
(1) |
|
|
Rifampin |
58 |
<0.12-4 |
1 |
2 |
<2 |
88 |
(47) |
|
|
Erythromycin |
28 |
32->128 |
128 |
>128 |
<0.5 |
0 |
(1) |
|
|
Erythromycin |
58 |
2->32 |
>32 |
>32 |
<0.5 |
0 |
(47) |
|
|
Chloramphenicol |
28 |
64-128 |
128 |
128 |
<8 |
0 |
(1) |
|
Chloramphenicol |
58 |
16->64 |
64 |
>64 |
<8 |
0 |
(47) |
|
Clindamycin |
28 |
0.5-8 |
4 |
8 |
<0.5 |
|
(1) |
|
Clindamycin |
58 |
0.5->32 |
8 |
16 |
<0.5 |
2 |
(47) |
|
|
Trimethoprim- sulfamethoxazoleg |
28 |
0.15-1.25 |
0.62 |
1.25 |
<2/38 |
100 |
(1) |
|
|
Trimethoprim- sulfamethoxazoleg |
58 |
0.5->32 |
4 |
8 |
<2/38 |
33 |
(47) |
|
|
Sulfamethoxazole |
28 |
32-128 |
128 |
128 |
|
|
(1) |
|
|
Linezolid |
58 |
8->16 |
>16 |
>16 |
|
|
(47) |
|
|
Vancomycin |
58 |
16->64 |
32 |
>64 |
<4 |
0 |
(47) |
|
|
Vancomycin |
28 |
8-16 |
16 |
16 |
<4 |
0 |
(1) |
|
|
|
|
|
|
|
|
|
|
|
a Modified from (1, 47, 66, 131)
b Current NCCLS interpretive standards for susceptibility (µg/ml) (92).
c The 58 isolates tested included: E. meningosepticum (37), C. indologenes (11), C. gleum (3), M. odoratum (4), and 4 unspeciated.
d
The 19 isolates tested included: E. meningosepticum (10), C.
indologenes (8), and one unspeciated.
e The 28 isolates tested included: E. meningosepticum (6) and
other species (22)
f No information provided on the species tested
g Trimethoprim-sulfamethoxazole tested in a ratio of 1:19. Concentration refers to the trimethoprim component
|
Table 2. In Vitro Susceptibilities of Elizabethkingia Meningosepticum a |
|||||||
|
Antibiotic |
n |
Range |
MIC50 |
MIC90 |
Breakpoint b |
% Susceptible |
Reference |
|
Amikacin |
9 |
≤2->64 |
64 |
>64 |
≤16 |
22 |
(109) |
|
Amikacin |
18 |
≥64 |
NS c |
NS |
≤16 |
0 |
(16) |
|
Amikacin |
10 |
≥64 |
>64 |
NS |
≤16 |
0 |
(44) |
|
Amikacin |
8 |
8-64 |
32 |
32 |
≤16 |
|
(114) |
|
Amikacin |
41 |
16->128 |
64 |
>128 |
≤16 |
|
(33) |
|
Gentamicin |
9 |
1->16 |
>16 |
>16 |
≤4 |
11 |
(109) |
|
Gentamicin |
18 |
2-≥16 |
NS |
NS |
≤4 |
6 |
(16) |
|
Gentamicin |
10 |
16->64 |
>64 |
NS |
≤4 |
0 |
(44) |
|
Gentamicin |
8 |
16-32 |
16 |
16 |
≤4 |
0 |
(117) |
|
Gentamicin |
41 |
8->128 |
64 |
>128 |
≤4 |
0 |
(33) |
|
Kanamycin |
10 |
>64 |
>64 |
NS |
≤16 |
0 |
(44) |
|
Netilmicin |
52 |
6.25->200 |
200 |
>200 |
≤8 |
|
(23) |
|
Netilmicin |
10 |
>64 |
>64 |
NS |
≤8 |
0 |
(44) |
|
Netilmicin |
41 |
32->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
|
Streptomycin |
10 |
≥64 |
>64 |
NS |
|
|
(44) |
|
Tobramycin |
18 |
8-≥16 |
NS |
NS |
≤4 |
0 |
(16) |
|
Tobramycin |
10 |
>64 |
>64 |
NS |
≤4 |
0 |
(44) |
|
Ampicillin |
18 |
16-≥32 |
NS |
NS |
|
|
(16) |
|
Ampicillin |
52 |
2->200 |
100 |
200 |
|
|
(23) |
|
Ampicillin |
10 |
64->128 |
128 |
NS |
|
|
(44) |
|
Mecillinam |
10 |
>128 |
>128 |
NS |
|
|
(44) |
|
Penicillin |
52 |
6.25-100 |
50 |
50 |
|
|
(23) |
|
Penicillin |
10 |
16->128 |
64 |
NS |
|
|
(44) |
|
Apalcillin d |
9 |
8-128 |
32 |
32 |
|
|
(109) |
|
Azlocillin |
10 |
32-64 |
64 |
NS |
|
|
(44) |
|
Carbenicillin |
10 |
>128 |
>128 |
NS |
≤16 |
0 |
(44) |
|
Mezlocillin |
18 |
≤16-≥256 |
NS |
NS |
≤16 |
67 |
(16) |
|
Mezlocillin |
10 |
8->128 |
32 |
NS |
≤16 |
|
(44) |
|
Piperacillin |
18 |
≤8-≥256 |
NS |
NS |
≤16 |
28 |
(16) |
|
Piperacillin |
52 |
1.6-12.5 |
6.25 |
12.5 |
≤16 |
100 |
(23) |
|
Piperacillin |
10 |
8-128 |
16 |
NS |
≤16 |
|
(44) |
|
Piperacillin |
41 |
1-32 |
4 |
8 |
≤16 |
|
(33) |
|
Piperacillin-tazobactam |
9 |
2->128 |
64 |
64 |
≤16/4 |
22 |
(109) |
|
Ticarcillin |
18 |
≤16-≥256 |
NS |
NS |
≤16 |
22 |
(16) |
|
Ticarcillin |
10 |
>128 |
>128 |
NS |
≤16 |
0 |
(44) |
|
Cefamandole |
10 |
32-128 |
64 |
NS |
≤8 |
0 |
(44) |
|
Cefazolin |
18 |
≥32 |
NS |
NS |
≤8 |
0 |
(16) |
|
Cefazolin |
10 |
≥128 |
>128 |
NS |
≤8 |
0 |
(44) |
|
Cefepime |
21 |
0.5->256 |
64 |
>256 |
≤8 |
19 |
(63) |
|
Cefoperazone |
8 |
16-32 |
32 |
32 |
≤16 |
|
(117) |
|
Cefoperazone |
41 |
16->128 |
32 |
64 |
≤16 |
|
(33) |
|
Cefpirome |
21 |
1->256 |
128 |
>256 |
|
19 |
(63) |
|
Cefotaxime |
52 |
1.6-50 |
12.5 |
25 |
≤8 |
|
(23) |
|
Cefotaxime |
10 |
16-64 |
32 |
NS |
≤8 |
0 |
(44) |
|
Cefotaxime |
8 |
16-64 |
16 |
32 |
≤8 |
0 |
(117) |
|
Cefotaxime |
41 |
16->128 |
32 |
128 |
≤8 |
0 |
(33) |
|
Cefoxitin |
18 |
8-≥32 |
NS |
NS |
≤8 |
11 |
(16) |
|
Cefoxitin |
10 |
4-64 |
8 |
NS |
≤8 |
|
(44) |
|
Cefsulodin |
8 |
≥128 |
≥128 |
≥128 |
|
|
(117) |
|
Ceftazidime |
18 |
≤8-≥32 |
NS |
NS |
≤8 |
6 |
(16) |
|
Ceftazidime |
52 |
6.25-200 |
50 |
100 |
≤8 |
|
(23) |
|
Ceftazidime |
8 |
≥128 |
≥128 |
≥128 |
≤8 |
0 |
(117) |
|
Ceftazidime |
41 |
2->128 |
>128 |
>128 |
≤8 |
|
(33) |
|
Ceftazidime |
10 |
4-256 |
128 |
256 |
≤8 |
|
(117) |
|
Ceftizoxime |
8 |
2-32 |
4 |
16 |
≤8 |
|
(117) |
|
Ceftriaxone |
18 |
16-≥64 |
NS |
NS |
≤8 |
0 |
(16) |
|
Ceftriaxone |
41 |
16->128 |
64 |
128 |
≤8 |
0 |
(33) |
|
Cefuroxime |
52 |
25->200 |
200 |
>200 |
≤8 |
0 |
(23) |
|
Cefuroxime |
10 |
≥128 |
≥128 |
NS |
≤8 |
0 |
(44) |
|
Cephalothin |
52 |
25->200 |
200 |
>200 |
≤8 |
0 |
(23) |
|
Cephalothin |
10 |
64->128 |
128 |
NS |
≤8 |
0 |
(44) |
|
Cephalothin |
41 |
>128->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
|
Moxalactam |
10 |
16->128 |
64 |
NS |
≤8 |
0 |
(44) |
|
Moxalactam |
8 |
16-64 |
16 |
32 |
≤8 |
0 |
(114) |
|
Moxalactam |
41 |
8->128 |
64 |
128 |
≤8 |
|
(33) |
|
Aztreonam |
18 |
≤8-≥32 |
NS |
NS |
≤8 |
11 |
(16) |
|
Aztreonam |
8 |
≥128 |
≥128 |
≥128 |
≤8 |
0 |
(117) |
|
Aztreonam |
41 |
128->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
|
Biapenem |
9 |
4-8 |
8 |
8 |
|
|
(109) |
|
Imipenem |
18 |
≥16 |
NS |
NS |
≤4 |
0 |
(16) |
|
Imipenem |
8 |
16-32 |
16 |
32 |
≤4 |
0 |
(117) |
|
Imipenem |
41 |
1-128 |
64 |
64 |
≤4 |
|
(33) |
|
Imipenem |
10 |
1-64 |
8 |
64 |
≤4 |
|
(126) |
|
Meropenem |
9 |
8->8 |
8 |
>8 |
|
|
(109) |
|
Thienamycin |
52 |
1.6-50 |
25 |
50 |
|
|
(23) |
|
Chloramphenicol |
52 |
6.25->200 |
50 |
100 |
≤8 |
|
(23) |
|
Chloramphenicol |
10 |
32>64 |
64 |
NS |
≤8 |
0 |
(44) |
|
Clindamycin |
9 |
0.5-8 |
4 |
8 |
≤0.5 |
11 |
(109) |
|
Clindamycin |
52 |
0.025-3.1 |
0.8 |
3.1 |
≤0.5 |
|
(23) |
|
Clindamycin |
10 |
0.5-16 |
1 |
NS |
≤0.5 |
|
(44) |
|
Ciprofloxacin |
9 |
0.5-2 |
1 |
2 |
≤1 |
67 |
(109) |
|
Ciprofloxacin |
18 |
<0.5-2 |
NS |
NS |
≤1 |
94 |
(16) |
|
Ciprofloxacin |
52 |
0.1-6.25 |
0.8 |
3.1 |
≤1 |
|
(23) |
|
Ciprofloxacin |
41 |
0.5-16 |
1 |
8 |
≤1 |
|
(33) |
|
Ciprofloxacin |
10 |
0.5-8 |
2 |
8 |
≤1 |
|
(126) |
|
Clinafloxacin |
9 |
0.12-1 |
0.25 |
0.5 |
|
|
(109) |
|
Clinafloxacin |
10 |
0.25-4 |
1 |
4 |
|
|
(126) |
|
Levofloxacin |
10 |
1-2 |
2 |
2 |
≤2 |
|
(126) |
|
DU-6859a |
9 |
1->4 |
2 |
>4 |
|
|
(109) |
|
Ofloxacin |
9 |
0.06-0.25 |
0.25 |
0.25 |
≤2 |
100 |
(109) |
|
Ofloxacin |
18 |
≤1-4 |
NS |
NS |
≤2 |
83 |
(16) |
|
Ofloxacin |
41 |
1-8 |
2 |
4 |
v2 |
|
(33) |
|
Ofloxacin |
10 |
1-4 |
4 |
4 |
v2 |
|
(126) |
|
Sparfloxacin |
10 |
0.016-4 |
0.5 |
4 |
|
|
(126) |
|
Trovafloxacin |
10 |
0.03-4 |
1 |
4 |
|
|
(126) |
|
Colistin |
10 |
>64 |
>64 |
NS |
|
|
(44) |
|
Trimethoprim-sulfamethoxazole e |
18 |
≤0.5-4 |
NS |
NS |
≤2/38 |
72 |
(16) |
|
Trimethoprim-sulfamethoxazole |
10 |
3.2->6.4 |
>6.4 |
NS |
≤2/38 |
0 |
(44) |
|
Trimethoprim |
41 |
1->16 |
8 |
>16 |
|
|
(33) |
|
Erythromycin |
52 |
0.1-200 |
0.8 |
3.1 |
≤0.5 |
|
(23) |
|
Erythromycin |
10 |
4-32 |
8 |
NS |
v0.5 |
0 |
(44) |
|
Erythromycin |
41 |
8->128 |
16 |
>128 |
≤0.5 |
0 |
(33) |
|
Clarithromycin |
9 |
1.5-16 |
6 |
8 |
v2 |
11 |
(109) |
|
Everninomicin |
9 |
2-8 |
2 |
2 |
|
|
(109) |
|
Fusidic acid |
52 |
3.1->200 |
100 |
>200 |
|
|
(23) |
|
Rifampin |
52 |
0.2-3.1 |
0.8 |
3.1 |
≤1 |
|
(23) |
|
Rifampin |
9 |
0.5-1 |
1 |
1 |
≤1 |
100 |
(109) |
|
Doxycycline |
9 |
1-16 |
2 |
4 |
≤4 |
89 |
(109) |
|
Doxycycline |
10 |
1-32 |
4 |
NS |
≤4 |
|
(44) |
|
Minocycline |
10 |
0.5-4 |
1 |
NS |
≤4 |
100 |
(44) |
|
Minocycline |
41 |
1-8 |
2 |
4 |
≤4 |
|
(33) |
|
Tetracycline |
52 |
25-200 |
100 |
100 |
≤4 |
|
(23) |
|
Tetracycline |
10 |
32->64 |
64 |
NS |
£4 |
0 |
(44) |
|
Vancomycin |
9 |
8-32 |
16 |
16 |
v4 |
0 |
(109) |
|
Vancomycin |
52 |
3.1-50 |
12.5 |
50 |
£4 |
|
(23) |
|
Vancomycin |
10 |
8-32 |
16 |
NS |
v4 |
0 |
(44) |
|
Vancomycin |
41 |
4-32 |
16 |
16 |
v4 |
|
(33) |
|
Teicoplanin |
9 |
8-32 |
8 |
16 |
≤8 |
56 |
(109) |
|
Teicoplanin |
41 |
8-64 |
16 |
32 |
≤8 |
|
(33) |
a
Modified from (16, 23,
33, 44,
63, 109,
117, 126).
b Current NCCLS interpretive standards for susceptibility (µg/ml)
(93)
c NS = not stated.
d Apalcillin in combinations with a ß-lactamase inhibitor, Ro48-1220
(4µg/ml).
e Trimethoprim-sulfamethoxazole tested in a ratio of 1:19.
Concentration refers to the trimethoprim component.
|
Table 3. In Vitro Susceptibilities of Chryseobacterium Indologenes a |
|
||||||||
|
Antibiotic |
n |
Range |
MIC50 |
MIC90 |
Breakpoint b |
% Susceptible |
Reference |
||
|
Amikacin |
12 |
32->128 |
64 |
>128 |
≤16 |
0 |
(60) |
||
|
Amikacin |
10 |
8-64 |
16 |
NS c |
≤16 |
|
(44) |
||
|
Amikacin |
4 |
2-32 |
8 |
32 |
≤16 |
|
(114) |
||
|
Amikacin |
59 |
32-128 |
128 |
>128 |
≤16 |
0 |
(33) |
||
|
Gentamicin |
12 |
8->128 |
64 |
>128 |
≤4 |
0 |
(60) |
||
|
Gentamicin |
10 |
2-16 |
8 |
NS |
≤4 |
|
(44) |
||
|
Gentamicin |
4 |
1-16 |
4 |
16 |
≤4 |
|
(114) |
||
|
Gentamicin |
59 |
8->128 |
128 |
>128 |
≤4 |
0 |
(33) |
||
|
Kanamycin |
10 |
≥64 |
≥64 |
NS |
≤16 |
0 |
(44) |
||
|
Netilmicin |
12 |
64->128 |
>128 |
>128 |
≤8 |
0 |
(60) |
||
|
Netilmicin |
10 |
8-64 |
16 |
NS |
≤8 |
|
(44) |
||
|
Netilmicin |
59 |
16->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
||
|
Streptomycin |
10 |
2->64 |
8 |
NS |
|
|
(44) |
||
|
Tobramycin |
10 |
≥64 |
≥64 |
NS |
≤4 |
0 |
(44) |
||
|
Penicillin |
18 |
2->128 |
>128 |
>128 |
|
|
(52) |
||
|
Penicillin |
10 |
4-128 |
8 |
NS |
|
|
(44) |
||
|
Ampicillin |
10 |
8->128 |
16 |
NS |
|
|
(44) |
||
|
Ampicillin |
18 |
1->128 |
>128 |
>128 |
|
|
(52) |
||
|
Amoxicillin-clavulinic acid |
18 |
1-32 |
32 |
32 |
≤8/4 |
11 |
(52) |
||
|
Mecillinam |
10 |
64->128 |
128 |
NS |
|
|
(44) |
||
|
Azlocillin |
10 |
0.5-16 |
2 |
NS |
|
|
(44) |
||
|
Carbenicillin |
10 |
32->128 |
32 |
NS |
≤16 |
0 |
(44) |
||
|
Mezlocillin |
10 |
1-8 |
4 |
NS |
≤16 |
100 |
(44) |
||
|
Piperacillin |
12 |
1-8 |
2 |
4 |
≤16 |
100 |
(60) |
||
|
Piperacillin |
10 |
0.25-4 |
1 |
NS |
≤16 |
100 |
(44) |
||
|
Piperacillin |
59 |
1->128 |
4 |
128 |
≤16 |
|
(33) |
||
|
Ticarcillin |
10 |
16->128 |
32 |
NS |
≤16 |
|
(44) |
||
|
Cefadroxyl |
18 |
8->128 |
>128 |
>128 |
|
|
(52) |
||
|
Cefamandole |
10 |
64->128 |
128 |
NS |
≤8 |
0 |
(44) |
||
|
Cefazolin |
10 |
32->128 |
64 |
NS |
≤8 |
0 |
(44) |
||
|
Cefoperazone |
12 |
4->128 |
8 |
16 |
≤16 |
92 |
(60) |
||
|
Cefoperazone |
4 |
2-8 |
4 |
8 |
≤16 |
100 |
(114) |
||
|
Cefoperazone |
59 |
2->128 |
16 |
>128 |
≤16 |
|
(33) |
||
|
Cefotaxime |
12 |
16->128 |
32 |
64 |
≤8 |
0 |
(60) |
||
|
Cefotaxime |
10 |
2-32 |
8 |
NS |
≤8 |
|
(44) |
||
|
Cefotaxime |
4 |
1-32 |
16 |
32 |
≤8 |
|
(114) |
||
|
Cefotaxime |
59 |
4->128 |
64 |
>128 |
≤8 |
|
(33) |
||
|
Cefoxitin |
10 |
4-64 |
8 |
NS |
≤8 |
|
(44) |
||
|
Cefsulodin |
4 |
≥128 |
≥128 |
≥128 |
|
|
(114) |
||
|
Ceftazidime |
12 |
2->128 |
8 |
8 |
≤8 |
92 |
(60) |
||
|
Ceftazidime |
4 |
0.5-4 |
2 |
4 |
≤8 |
100 |
(114) |
||
|
Ceftazidime |
59 |
2->128 |
8 |
32 |
≤8 |
|
(33) |
||
|
Ceftazidime |
9 |
2->256 |
16 |
NS |
≤8 |
|
(123)d |
||
|
Cefepime |
96 |
0.25->256 |
4 |
16 |
≤8 |
73 |
(63) |
||
|
Cefpirome |
96 |
0.25->256 |
8 |
128 |
|
64 |
(63) |
||
|
Ceftizoxime |
4 |
4-32 |
16 |
32 |
≤8 |
|
(114) |
||
|
Ceftriaxone |
12 |
16->128 |
32 |
64 |
≤8 |
0 |
(60) |
||
|
Ceftriaxone |
59 |
16->128 |
32 |
>128 |
≤8 |
0 |
(33) |
||
|
Cefuroxime |
18 |
1->128 |
>128 |
>128 |
≤8 |
6 |
(52) |
||
|
Cefuroxime |
10 |
16->128 |
32 |
NS |
≤8 |
0 |
(44) |
||
|
Cephalexin |
18 |
8->128 |
>128 |
>128 |
|
|
(52) |
||
|
Cephalothin |
12 |
32->128 |
>128 |
>128 |
≤8 |
0 |
(60) |
||
|
Cephalothin |
10 |
16->128 |
64 |
NS |
≤8 |
0 |
(44) |
||
|
Cephalothin |
59 |
32->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
||
|
Moxalactam |
12 |
32->128 |
64 |
>128 |
≤8 |
0 |
(60) |
||
|
Moxalactam |
10 |
16-64 |
16 |
NS |
≤8 |
0 |
(44) |
||
|
Moxalactam |
4 |
8-32 |
8 |
32 |
≤8 |
|
(114) |
||
|
Moxalactam |
59 |
32->128 |
64 |
128 |
≤8 |
0 |
(33) |
||
|
Aztreonam |
12 |
>128 |
>128 |
>128 |
≤8 |
0 |
(60) |
||
|
Aztreonam |
4 |
≥128 |
≥128 |
≥128 |
≤8 |
0 |
(114) |
||
|
Aztreonam |
59 |
>128->128 |
>128 |
>128 |
≤8 |
0 |
(33) |
||
|
Imipenem |
12 |
32->128 |
64 |
64 |
≤4 |
0 |
(60) |
||
|
Imipenem |
4 |
4-32 |
4 |
32 |
≤4 |
|
(114) |
||
|
Imipenem |
59 |
1->128 |
64 |
>128 |
≤4 |
|
(33) |
||
|
Imipenem |
9 |
1-64 |
32 |
NS |
≤4 |
|
(123)d |
||
|
Chloramphenicol |
10 |
32->64 |
32 |
NS |
≤8 |
0 |
(44) |
||
|
Clindamycin |
12 |
4 |
4 |
4 |
≤0.5 |
0 |
(60) |
||
|
Clindamycin |
10 |
0.13->64 |
0.5 |
NS |
≤0.5 |
|
(44) |
||
|
Ciprofloxacin |
12 |
0.5-128 |
1 |
32 |
≤1 |
67 |
(60) |
||
|
Ciprofloxacin |
18 |
0.5-1 |
0.5 |
0.5 |
≤1 |
100 |
(52) |
||
|
Ciprofloxacin |
59 |
0.25-128 |
2 |
128 |
≤1 |
|
(33) |
||
|
Ciprofloxacin |
9 |
0.25-8 |
1 |
NS |
≤1 |
|
(123)d |
||
|
Clinafloxacin |
9 |
0.125-2 |
0.5 |
|
|
|
(123)d |
||
|
Enoxacin |
18 |
0.5-4 |
1 |
2 |
≤2 |
94 |
(52) |
||
|
Levofloxacin |
9 |
0.25-4 |
1 |
NS |
≤2 |
|
(126)d |
||
|
Ofloxacin |
12 |
2-64 |
2 |
32 |
≤2 |
50 |
(60) |
||
|
Ofloxacin |
18 |
0.25-2 |
0.25 |
1 |
≤2 |
100 |
(52) |
||
|
Ofloxacin |
59 |
0.5-64 |
8 |
64 |
≤2 |
|
(33) |
||
|
Ofloxacin |
9 |
0.5-8 |
2 |
NS |
≤2 |
|
(126)d |
||
|
Sparfloxacin |
9 |
0.016-2 |
0.25 |
NS |
|
|
(126)d |
||
|
Trovofloxacin |
9 |
0.016-2 |
0.125 |
NS |
|
|
(126)d |
||
|
Trimethoprim-sulfamethoxazole e |
12 |
0.5-16 |
2 |
16 |
≤2/38 |
50 |
(60) |
||
|
Trimethoprim-sulfamethoxazole |
10 |
0.2-1.6 |
0.4 |
NS |
≤2/38 |
100 |
(44) |
||
|
Trimethoprim |
59 |
0.25-16 |
4 |
16 |
|
|
(33) |
||
|
Erythromycin |
12 |
64->128 |
>128 |
>128 |
≤0.5 |
0 |
(60) |
||
|
Erythromycin |
10 |
1-16 |
2 |
NS |
≤0.5 |
0 |
(44) |
||
|
Erythromycin |
59 |
8->128 |
128 |
>128 |
≤0.5 |
0 |
(33) |
||
|
Doxycycline |
10 |
1-8 |
4 |
NS |
≤4 |
|
(44) |
||
|
Minocycline |
12 |
2-16 |
4 |
4 |
≤4 |
92 |
(60) |
||
|
Minocycline |
10 |
1-4 |
1 |
NS |
≤4 |
100 |
(44) |
||
|
Minocycline |
59 |
1-16 |
4 |
8 |
≤4 |
|
(33) |
||
|
Tetracycline |
18 |
4-32 |
16 |
32 |
≤4 |
29 |
(52) |
||
|
Tetracycline |
10 |
4-32 |
16 |
NS |
≤4 |
|
(44) |
||
|
Vancomycin |
12 |
2-128 |
16 |
16 |
≤4 |
8 |
(60) |
||
|
Vancomycin |
10 |
16->64 |
16 |
NS |
≤4 |
0 |
(44) |
||
|
Vancomycin |
59 |
2->128 |
16 |
16 |
≤4 |
|
(33) |
||
|
Teicoplanin |
12 |
32-64 |
32 |
64 |
≤8 |
0 |
(60) |
||
|
Teicoplanin |
59 |
16->128 |
32 |
32 |
≤8 |
0 |
(33) |
||
|
Colistin |
10 |
>64 |
>64 |
NS |
|
|
(44) |
||
|
|
|
|
|
|
|
|
|
|
|
a
Modified from (33, 44,
52, 60,
114, 126).
b Current NCCLS interpretive standards for susceptibility (µg/ml)
(94)
c NS = not stated.
d Includes Chryseobacterium gleum strains
e Trimethoprim-sulfamethoxazole tested in a combination of 1:19. Concentration refers to the trimethoprim component.
|
Table 4. In Vitro Susceptibilities of Myroides Species a |
|
|
|||||
|
Antibiotic |
n |
Range |
MIC50 |
MIC90 |
Breakpoint b |
% Susceptible |
Reference |
|
Amikacin |
5 |
>64 |
>64 |
NS c |
≤16 |
0 |
(44) |
|
Amikacin |
17 |
64->128 |
>128 |
>128 |
≤16 |
0 |
(57) |
|
Amikacin |
6 |
>128->128 |
>128 |
NS |
≤16 |
0 |
(44) |
|
Gentamicin |
5 |
>64 |
>64 |
NS |
≤4 |
0 |
(44) |
|
Gentamicin |
26 |
64->128 |
>128 |
>128 |
≤4 |
0 |
(57) |
|
Gentamicin |
6 |
>128->128 |
>128 |
NS |
≤4 |
0 |
(44) |
|
Kanamycin |
5 |
>64 |
>64 |
NS |
≤16 |
0 |
(44) |
|
Kanamycin |
26 |
>128 |
>128 |
>128 |
≤16 |
0 |
(57) |
|
Netilmicin |
5 |
>64 |
>64 |
NS |
≤8 |
0 |
(44) |
|
Netilmicin |
6 |
>128->128 |
>128 |
NS |
≤8 |
0 |
(44) |
|
Streptomycin |
5 |
>64 |
>64 |
NS |
|
|
(44) |
|
Streptomycin |
26 |
64->128 |
>128 |
>128 |
|
|
(57) |
|
Tobramycin |
5 |
>64 |
>64 |
NS |
≤4 |
0 |
(44) |
|
Tobramycin |
17 |
>128 |
>128 |
>128 |
≤4 |
0 |
(57) |
|
Ampicillin |
5 |
1->128 |
16 |
NS |
|
|
(44) |
|
Ampicillin |
26 |
4->128 |
32 |
128 |
|
|
(57) |
|
Penicillin |
5 |
1->128 |
4 |
NS |
|
|
(44) |
|
Mecillinam |
5 |
>128 |
>128 |
NS |
|
|
(44) |
|
Azlocillin |
5 |
16->128 |
16 |
NS |
|
|
(44) |
|
Carbenicillin |
5 |
8->128 |
128 |
NS |
≤16 |
|
(44) |
|
Carbenicillin |
26 |
32->128 |
128 |
>128 |
≤16 |
0 |
(57) |
|
Mezlocillin |
5 |
8->128 |
16 |
NS |
≤16 |
|
(44) |
|
Piperacillin |
5 |
16->128 |
16 |
NS |
≤16 |
|
(44) |
|
Piperacillin |
6 |
4->128 |
>128 |
NS |
≤16 |
|
(33) |
|
Ticarcillin |
5 |
1->128 |
64 |
NS |
≤16 |
|
(44) |
|
Cefamandole |
5 |
≥128 |
≥128 |
NS |
≤8 |
0 |
(44) |
|
Cefuroxime |
5 |
128 |
128 |
NS |
≤8 |
0 |
(44) |
|
Cefazolin |
5 |
≥128 |
≥128 |
NS |
≤8 |
0 |
(44) |
|
Cefoperazone |
6 |
16->128 |
>128 |
NS |
≤16 |
|
(33) |
|
Cefotaxime |
5 |
64-128 |
64 |
NS |
≤8 |
0 |
(44) |
|
Cefotaxime |
6 |
64->128 |
>128 |
NS |
≤8 |
0 |
(33) |
|
Ceftazidime |
6 |
4->128 |
>128 |
NS |
≤8 |
|
(33) |
|
Ceftriaxone |
6 |
128->128 |
>128 |
NS |
≤8 |
0 |
(33) |
|
Cephaloridine |
26 |
1-128 |
8 |
16 |
|
|
(57) |
|
Cephalothin |
5 |
64->128 |
64 |
NS |
≤8 |
0 |
(44) |
|
Cephalothin |
6 |
128->128 |
>128 |
NS |
≤8 |
0 |
(33) |
|
Moxalactam |
5 |
8-128 |
32 |
NS |
≤8 |
|
(44) |
|
Moxalactam |
6 |
16-64 |
64 |
NS |
≤8 |
0 |
(33) |
|
Aztreonam |
6 |
32->128 |
>128 |
NS |
≤8 |
0 |
(33) |
|
Imipenem |
6 |
8-32 |
16 |
NS |
≤4 |
0 |
(33) |
|
Chloramphenicol |
5 |
4-32 |
32 |
NS |
≤8 |
|
(44) |
|
Chloramphenicol |
26 |
4->128 |
16 |
32 |
≤8 |
|
(57) |
|
Clindamycin |
5 |
0.13-1 |
0.5 |
NS |
≤0.5 |
|
(44) |
|
Ciprofloxacin |
6 |
1-64 |
32 |
NS |
≤1 |
|
(33) |
|
Ofloxacin |
6 |
2-64 |
32 |
NS |
≤2 |
|
(33) |
|
Colistin |
5 |
>64 |
>64 |
NS |
|
|
(44) |
|
Trimethoprim- sulfamethoxazole d |
5 |
0.4->6.4 |
>6.4 |
NS |
≤2/38 |
|
(44) |
|
Trimethoprim- sulfamethoxazole |
26 |
0.2->6.4 |
3.2 |
6.4 |
≤2/38 |
|
(57) |
|
Sulfamethoxazole |
26 |
1->128 |
>128 |
>128 |
|
|
(57) |
|
Trimethoprim |
6 |
4->16 |
>16 |
NS |
|
|
(33) |
|
Erythromycin |
5 |
4 |
4 |
NS |
≤0.5 |
0 |
(44) |
|
Erythromycin |
26 |
<1->128 |
2 |
4 |
≤0.5 |
|
(57) |
|
Erythromycin |
6 |
64->128 |
>128 |
NS |
≤0.5 |
0 |
(33) |
|
Minocycline |
5 |
0.5-2 |
0.5 |
NS |
≤4 |
100 |
(44) |
|
Minocycline |
6 |
2-8 |
2 |
NS |
≤4 |
|
(33) |
|
Doxycycline |
5 |
0.5-8 |
1 |
NS |
≤4 |
|
(44) |
|
Tetracycline |
5 |
4->64 |
64 |
NS |
≤4 |
|
(44) |
|
Tetracycline |
26 |
4-128 |
64 |
128 |
≤4 |
|
(57) |
|
Vancomycin |
5 |
32->64 |
>64 |
NS |
≤4 |
0 |
(44) |
|
Vancomycin |
6 |
16-64 |
64 |
NS |
≤4 |
0 |
(33) |
|
Teicoplanin |
6 |
16->128 |
>128 |
NS |
≤8 |
0 |
(33) |
|
Polymyxin B |
26 |
64->128 |
>128 |
>128 |
|
|
(57) |
|
Nalidixic acid |
26 |
8-32 |
8 |
16 |
|
|
(57) |
a Modified from, (33, 44, 57, 126).
b Current NCCLS interpretive standards for susceptibility (µg/ml) (93)
c NS = not stated.
d Trimethoprim-sulfamethoxazole tested in a ratio of 1:19. Concentration refers to the trimethoprim component.
Version with rev. refs on 3/15/11